This study is testing a drug called brenipatide in adults with schizophrenia. Researchers want to see if brenipatide, when given along with your usual schizophrenia medication, is safe and effective compared to a placebo (an inactive substance). You might be able to join if you are 18 to 55 years old, have schizophrenia, and are on a stable medication regimen. If you've had schizophrenia for more than 6 years, you must have experienced at least one relapse in the last three years. The main goal is to see how brenipatide affects body weight over 52 weeks in participants with a BMI of 25.0 kg/m² or higher. The study plans to enroll 450 participants, but its current recruitment status is unclear.

Study design

This is an interventional study comparing brenipatide to a placebo. It plans to enroll 450 adult participants.

What's involved

Your participation could last up to approximately 15 months, including a 1-month screening, up to 12 months of treatment, and about 2 months of follow-up.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for approximately 2 months after the treatment period, with body weight measured at Week 52.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.